Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBOXA for Inoperable NET Liver Metastases
NCT03881306Phase 2Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in Neuroendocrine Neoplasm (NEN), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Disease Control Rate at 2 years. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03881306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03881306.